Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts
Authors
Keywords
-
Journal
LABORATORY INVESTIGATION
Volume 92, Issue 7, Pages 952-966
Publisher
Springer Nature
Online
2012-04-30
DOI
10.1038/labinvest.2012.65
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Metronomic UFT/Cyclophosphamide Chemotherapy and Antiangiogenic Drug Assessed in a New Preclinical Model of Locally Advanced Orthotopic Hepatocellular Carcinoma
- (2015) Terence C. Tang et al. NEOPLASIA
- Loss of Tumor-Initiating Cell Activity in Cyclophosphamide-Treated Breast Xenografts
- (2014) Steven P. Zielske et al. Translational Oncology
- Isolation of Circulating Tumor Cells in Patients with Hepatocellular Carcinoma Using a Novel Cell Separation Strategy
- (2011) W. Xu et al. CLINICAL CANCER RESEARCH
- Evidence of Distinct Tumour-Propagating Cell Populations with Different Properties in Primary Human Hepatocellular Carcinoma
- (2011) Federico Colombo et al. PLoS One
- The Power and the Promise of Liver Cancer Stem Cell Markers
- (2011) Li-Li Liu et al. STEM CELLS AND DEVELOPMENT
- Sex-related efficiency in NSG mouse engraftment
- (2010) I. Martin-Padura et al. BLOOD
- Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma
- (2010) Yu-Yun Shao et al. CANCER
- Cancer stem cells and hepatocellular carcinoma
- (2010) Zhixing Yao et al. CANCER BIOLOGY & THERAPY
- Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: An in vivo bioluminescence imaging study
- (2010) Qing Zeng et al. EUROPEAN JOURNAL OF CANCER
- Sorafenib: Where do we go from here?
- (2010) Abby B. Siegel et al. HEPATOLOGY
- Octamer 4 (Oct4) mediates chemotherapeutic drug resistance in liver cancer cells through a potential Oct4-AKT-ATP-binding cassette G2 pathway
- (2010) Xiao Qi Wang et al. HEPATOLOGY
- CD13 is a therapeutic target in human liver cancer stem cells
- (2010) Naotsugu Haraguchi et al. JOURNAL OF CLINICAL INVESTIGATION
- Current and emerging concepts in tumour metastasis
- (2010) Caroline Coghlin et al. JOURNAL OF PATHOLOGY
- Metronomic chemotherapy: new rationale for new directions
- (2010) Eddy Pasquier et al. Nature Reviews Clinical Oncology
- EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
- (2010) A Singh et al. ONCOGENE
- The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells
- (2009) Angelo Cicalese et al. CELL
- Significance of CD90+ Cancer Stem Cells in Human Liver Cancer
- (2008) Zhen Fan Yang et al. CANCER CELL
- Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
- (2008) D. Y. Chiang et al. CANCER RESEARCH
- Stem Cells and Niches: Mechanisms That Promote Stem Cell Maintenance throughout Life
- (2008) Sean J. Morrison et al. CELL
- Validation of a Standardized Method for Enumerating Circulating Endothelial Cells and Progenitors: Flow Cytometry and Molecular and Ultrastructural Analyses
- (2008) P. Mancuso et al. CLINICAL CANCER RESEARCH
- EpCAM-Positive Hepatocellular Carcinoma Cells Are Tumor-Initiating Cells With Stem/Progenitor Cell Features
- (2008) Taro Yamashita et al. GASTROENTEROLOGY
- Gene Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma
- (2008) Yujin Hoshida et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now